Morysa (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Morysa, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to preserve neuronal function and improve cognition.

GNH USA supplies Morysa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Morysa (memantine hydrochloride) acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease. - Alzheimer's disease (moderate to severe): Improves cognition, functional abilities, and behavioral symptoms in patients with moderate to severe disease. - Alzheimer's disease (mild to moderate): May provide modest cognitive benefit when used early in the disease course. - Behavioral symptoms of Alzheimer’s disease: Can help reduce agitation and aggression associated with the condition.

Morysa may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient mental clouding. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Cardiac arrhythmia: irregular heart rhythm. - Suicidal thoughts: emergence of depressive or suicidal ideation.

When prescribing Morysa, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: use with caution in patients with uncontrolled hypertension or arrhythmias. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Concomitant NMDA antagonists: avoid combining with other agents that block NMDA receptors. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Morysa can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can cause severe central nervous system depression. - Other NMDA antagonists: risk of excessive inhibition of glutamatergic signaling.

Moderate Interactions (Monitor Closely): - Antihypertensives: memantine may enhance hypotensive effects. - Diuretics: increased risk of dehydration and electrolyte imbalance. - Anticholinergic drugs: may diminish cognitive benefits of memantine.